Stories about Medizinische Behandlung
- more
What Our Genetic Information Tells Us About Type 2 Diabetes Risk and Complications
moreHearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study
Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first patient for the PROHEAR-Study. The PROHEAR-Study is a placebo-controlled, Phase 2a study with split-body design, which investigates the otoprotective efficacy ...
moreINSIGHTEC MR-GUIDED FOCUSED ULTRASOUND TECHNOLOGY RECOMMENDED FOR NATIONAL COVERAGE FOR DUTCH PATIENTS LIVING WITH ESSENTIAL TREMOR
Amsterdam (ots/PRNewswire) - The Netherlands is the latest European country to recommend national coverage for the treatment of essential tremor with focused ultrasound. Insightec, a pioneer and global leader in focused ultrasound, has welcomed a positive recommendation report[1] from the Dutch Healthcare Institute ...
more- 2
OPTIMA cancer project announces the Region Uppsala as new partner
more Epitomee® Announces Successful Completion of Pivotal Clinical Trial for Innovative Weight Loss Capsule
Caesarea, Israel (ots/PRNewswire) - Epitomee® announces the successful completion of the RESET pivotal clinical trial, for its weight loss capsule. The randomized placebo controlled, double blind trial, investigated the safety and efficacy of Epitomee® capsule versus the sham capsule control, alongside lifestyle ...
moreAcousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease
Tübingen (ots) - - German pioneer biotech accelerates hearing loss solution development with fresh capital boost Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition to its esteemed group of investors. The infusion of fresh ...
moreMedison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
Zug, Switzerland (ots/PRNewswire) - - Libtayo (cemiplimab) is a leading PD-1 inhibitor that has shown efficacy in the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer, and is approved by regulatory ...
moreNew Source of Stem Cells in Injury-Affected Brains of Patients
moreTakeda Pharma Vertrieb GmbH & Co. KG
The European Commission Approves Label Update for TAKHZYRO® (lanadelumab), Expanding Its Use to a Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (HAE)
Zurich (ots/PRNewswire) - - TAKHZYRO® is the First Routine Prevention Treatment of HAE Approved in the EU for Patients Under the Age of Six. - The therapeutical indication for TAKHZYRO® has been extended to patients aged 2 years and older.1 - Offers a New Preventative Treatment Option for young HAE patients with ...
moreBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
moreBehaVR and Fern Health Merge To Form RealizedCare, Launch Digital Care Management Platform to Unlock the Value of Digital Therapeutics
NASHVILLE, Tenn., Aachen, Germany (ots) - The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise BehaVR, a pioneering force in digital therapeutics (DTx) experiences, and Fern ...
moreIpsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)
Zug, Switzerland and Paris (ots/PRNewswire) - Bylvay (odevixibat) is the first and only oral treatment available in Canada for the treatment of pruritus due to this rare genetic condition Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, ...
moreSoterios Pharma completes Phase II enrolment for STS-01 in mild / moderate (patchy) alopecia areata
London (ots/PRNewswire) - Soterios Pharma, a privately held clinical-stage pharmaceutical company, announced today that it has completed target enrolment for its Phase II trial with STS-01 for mild / moderate (patchy) alopecia areata. Final results of the study are anticipated to be available in Q2 2024. David Fleet, CEO of Soterios Pharma, said, "This represents an ...
more- 3
EU Provides 1 Mio. to Researchers to Advance Personalised Oncology
One documentmore Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots/PRNewswire) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic ...
moreHearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial
Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing loss, received approval from the German regulatory authorities (BfArM) for its groundbreaking Phase 2 clinical trial of the etiology-agnostic otoprotectant ...
moreTakeda Pharma Vertrieb GmbH & Co. KG
Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema (HAE) in Patients Aged 2 years and Older
Zurich (ots/PRNewswire) - - If Approved, Lanadelumab Will be the First Long-Term Prophylactic Treatment of HAE Available in the EU for Patients Under the Age of Six. - Positive Opinion Based on Pivotal Study SHP643-301, Evaluating the Safety Profile and Pharmacokinetics (PK) of Lanadelumab, in Combination with ...
morePress Release: Exercise and Muscle Regulation: Implications for Diabetes and Obesity
How do our muscles respond at the molecular level to exercise? Researchers at Helmholtz Munich and the German Institute of Human Nutrition Potsdam-Rehbrücke (DIfE) have unraveled the cellular basis and signaling pathways responsible for the p ositive impact of physical activity ...
moreTake a Deep Breath: Early Detection of Vascular Disease in Chronic Lung Disease of Premature Infants
Premature infants often struggle with breathing and require ventilatory support and oxygen therapy. Unfortunately, this might lead to lung damage resulting in lifelong consequences and chronic disease. Dr. Anne Hilgendorff’s team from Helmholtz Munich and the LMU University Hospital developed a non-invasive ...
moreOD-OS GmbH at ESCRS 2023: Recent MDR certification of Navilas® underlines its advanced standard in retina lasers and opens path to new developments
moreIsotopia Issues a call to action to the radionuclide Therapy industry.
Petah Tikva, Israel (ots/PRNewswire) - Isotopia Molecular Imaging is a global pharmaceutical company that develops, produces, and distributes therapeutic and diagnostic radioactive isotopes. "If you are in the Lu-177 field, don't miss this information." The Lu-177 radiopharmaceuticals sector stands at a critical juncture, necessitating urgent collaboration. Our shared ...
more- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
One documentmore Johnson & Johnson Vision announces launch of ELITA™ Platform to Correct Myopia with New SILK Procedure at the European Society of Cataract and Refractive Surgeons Congress
London (ots/PRNewswire) - Next-generation laser vision correction provides next-day results and recovery1,2 - The next-generation ELITATM Femtosecond Laser to correct myopia with the new SILK procedure** - The latest innovation in extended depth of focus (EDOF) intraocular lenses (IOLs) will be shared with invited ...
moreHuma collaborates with Google Cloud to improve healthcare through generative AI
New York (ots/PRNewswire) - - Huma aims to further support patients and the healthcare workforce by enhancing its regulated Software as Medical Device (SaMD) platform with the addition of generative AI applications - Huma is leveraging Google Cloud's Vertex AI platform and exploring the use of other Google GenAI tools such as Med-PaLM 2 - Huma and Google Cloud are ...
moreHearing loss company Acousia Therapeutics to present key learnings and data from lead development programs at US and European meetings in August and September
Tübingen, Germany (ots) - Acousia Therapeutics GmbH to share key learnings and data from its lead candidate development programs — clinical stage ACOU085 and late preclinical stage ACOU082 — during four presentations at industry and research meetings from August 29 to September 5. From August 29–31, Acousia ...
moreA New Ally in Fighting Brain Diseases: Our Very Own Skull
more- 4
PIONEER Big Data in Prostate Cancer Platform Opens up to Asian Data Sets
more - 2
CARAMBA: New Hope for Multiple Myeloma Patients
more RHEACELL announces “First Patient In”: EB-Haus in Salzburg, Austria starts pivotal study for stem cell therapy for severe forms of Epidermolysis bullosa that is longed for by those affected
more